Abstract
Enterovirus 71 (EV71) infection can cause hand–foot-and-mouth disease (HFMD). Inactivated EV71 vaccine was effective to prevent EV71 derived HFMD. A highly efficient and economical process for producing EV71 is needed. In our study, the epidemic strain of EV71 (EV71-2013ZJHFMD) was obtained and purified. The Vero cells were cultured for production of EV71. The mini-bioreactor vessel (Amprotein Inc., China) packed with a 0.6 g polymer fiber carrier was used to determine the best seeding cell density, multiplicity of infection (MOI) and temperature. Then the optimized procedure was further applied in a 10 L disposable perfusion bioreactor ACPB (AmProtein Current Perfusion Bioreactor). The Vero cell culture and viral titer were monitored. The seeding density of 1.5 × 107 cells per 0.6 g disk was considered to be the most appropriate for the culture. The best MOI was 0.1 and the temperature was 32 °C. The total cell number increased from 1.5 × 109 to 3.0 × 1010. The maximum viral titers reached 1.0 × 108/mL 3 days post-infection in our optimized special culture procedure (serum-free during the harvest period, supplemented with 0.25% Lactalbumin Hydrolysate). The total volume of the harvested supernatant was 25 L and the total virus yield was 1.93 × 1012. The procedure using Vero cells grown on polymer fiber paper carriers was effective for the large-scale production of EV71.
Similar content being viewed by others
References
Butler M et al (2000) Application of a serum-free medium for the growth of Vero cells and the production of reovirus. Biotechnol Prog 16:854–858. https://doi.org/10.1021/bp000110+
Chang LY et al (1999) Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18:1092–1096
Chang JY et al (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 30:703–711. https://doi.org/10.1016/j.vaccine.2011.11.087
Chatproedprai S, Theanboonlers A, Korkong S, Thongmee C, Wananukul S, Poovorawan Y (2010) Clinical and molecular characterization of hand–foot-and-mouth disease in Thailand, 2008–2009. Jpn J Infect Dis 63:229–233
Chen KD, Wu XX, Yu DS, Ou HL, Li YH, Zhou YQ, Li LJ (2018) Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system. Appl Microbiol Biotechnol 102:6469–6477. https://doi.org/10.1007/s00253-018-9091-5
Chong P et al (2012) Production of EV71 vaccine candidates. Hum Vaccines Immunother 8:1775–1783. https://doi.org/10.4161/hv.21739
Chou AH et al (2012) Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS ONE 7:e34834. https://doi.org/10.1371/journal.pone.0034834
Gao LD et al (2014) Correlation analysis of EV71 detection and case severity in hand, foot, and mouth disease in the Hunan Province of China. PLoS ONE 9:e100003. https://doi.org/10.1371/journal.pone.0100003
Hu AY et al (2011) Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS ONE 6:e14578. https://doi.org/10.1371/journal.pone.0014578
Huang Y et al (2015) Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009–2013. J Med Virol 87:1471–1479. https://doi.org/10.1002/jmv.24200
Iwai M et al (2009) Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 62:254–259
Li W et al (2013) Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period. PLoS ONE 8:e80515. https://doi.org/10.1371/journal.pone.0080515
Lin YC, Wu CN, Shih SR, Ho MS (2002) Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20:2485–2493. https://doi.org/10.1016/S0264-410X(02)00182-2
Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25:19–24. https://doi.org/10.1016/j.vaccine.2006.06.083
Liu CC et al (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE 6:e20005. https://doi.org/10.1371/journal.pone.0020005
Liu W et al (2015) Spatiotemporal dynamics of hand-foot-mouth disease and its relationship with meteorological factors in Jiangsu Province, China. PLoS ONE 10:e0131311. https://doi.org/10.1371/journal.pone.0131311
Ma S et al (2015) Dynamic constitution of the pathogens inducing encephalitis in hand, foot and mouth disease in Kunming, 2009–2011. Jpn J Infect Dis 68:504–510. https://doi.org/10.7883/yoken.JJID.2014.428
Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778–790. https://doi.org/10.1016/S1473-3099(10)70194-8
Takahashi S et al (2016) Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med 13:e1001958. https://doi.org/10.1371/journal.pmed.1001958
Van Tu P et al (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13:1733–1741. https://doi.org/10.3201/eid1311.070632
Wu SC, Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22:3858–3864. https://doi.org/10.1016/j.vaccine.2004.05.037
Wu CY et al (2015) Inactivated enterovirus 71 vaccine produced by 200-L scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse. PLoS ONE 10:e0136420. https://doi.org/10.1371/journal.pone.0136420
Xiao X et al (2016) Comparisons between mild and severe cases of hand, foot and mouth disease in temporal trends: a comparative time series study from mainland China. BMC Public Health 16:1109. https://doi.org/10.1186/s12889-016-3762-x
Xing W et al (2014) Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis 14:308–318. https://doi.org/10.1016/S1473-3099(13)70342-6
Xu W et al (2012) Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 9:8. https://doi.org/10.1186/1743-422X-9-8
Yang B, Wu P, Wu JT, Lau EH, Leung GM, Yu H, Cowling BJ (2015) Seroprevalence of enterovirus 71 antibody among children in China: a systematic review and meta-analysis. Pediatr Infect Dis J 34:1399–1406. https://doi.org/10.1097/INF.0000000000000900
Yin XG, Yi HX, Shu J, Wang XJ, Wu XJ, Yu LH (2014) Clinical and epidemiological characteristics of adult hand, foot, and mouth disease in northern Zhejiang, China, May 2008–November 2013. BMC Infect Dis 14:251. https://doi.org/10.1186/1471-2334-14-251
Zhao J, Jiang F, Zhong L, Sun J, Ding J (2016) Age patterns and transmission characteristics of hand, foot and mouth disease in China. BMC Infect Dis 16:691. https://doi.org/10.1186/s12879-016-2008-y
Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC (2016) Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines 15:803–813. https://doi.org/10.1080/14760584.2016.1191357
Acknowledgements
This work was supported by the State Project of Essential Drug Research and Development [Grant number 2015ZX09101044] and the Science & Technology Key Program of Zhejiang, China [Grant number 2014C03039].
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wu, XX., Chen, KD., Chen, DZ. et al. Process optimization for the rapid production of Enterovirus 71. Cytotechnology 71, 1053–1061 (2019). https://doi.org/10.1007/s10616-019-00340-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-019-00340-3